Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OPKO Health, Inc.    OPK

OPKO HEALTH, INC.

(OPK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

OPKO Health Up 12% After Study Data

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/21/2019 | 08:45am EST

By Michael Dabaie

OPKO Health shares were up 12%, to $2.34, in premarket trading Monday.

OPKO and Pfizer said the Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth-hormone deficiency met its primary endpoint of non-inferiority to daily Genotropin for injection, as measured by annual height velocity at 12 months.

The results demonstrated the potential to reduce current dosing frequency from once-daily to a single weekly injection, the companies said.

In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD. OPKO is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product.

Pfizer shares were up 0.6% premarket, to $36.66.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
OPKO HEALTH, INC. -1.71% 1.435 Delayed Quote.-51.50%
PFIZER 0.22% 37.015 Delayed Quote.-15.40%
PFIZER LTD -0.77% 3994.1 End-of-day quote.41.48%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OPKO HEALTH, INC.
11/05OPKO HEALTH : 3Q Earnings Snapshot
AQ
11/05OPKO HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
11/05OPKO HEALTH, INC. : Results of Operations and Financial Condition, Regulation FD..
AQ
11/05OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Resu..
GL
11/04OPKO HEALTH : to Report Third Quarter 2019 Financial Results on November 5, 2019
AQ
11/04BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating ..
GL
11/01OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 201..
GL
10/30OPKO HEALTH, INC. : Entry into a Material Definitive Agreement, Financial Statem..
AQ
10/24OPKO Health, Inc. Announces Pricing of its Offering of Common Stock
GL
10/22OPKO Health, Inc. Announces Proposed Offering of Common Stock
GL
More news
Financials (USD)
Sales 2019 896 M
EBIT 2019 -210 M
Net income 2019 -256 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -3,52x
P/E ratio 2020 -6,63x
Capi. / Sales2019 1,10x
Capi. / Sales2020 1,07x
Capitalization 985 M
Chart OPKO HEALTH, INC.
Duration : Period :
OPKO Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPKO HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 4,50  $
Last Close Price 1,48  $
Spread / Highest target 305%
Spread / Average Target 204%
Spread / Lowest Target 103%
EPS Revisions
Managers
NameTitle
Phillip Frost Chairman & Chief Executive Officer
Jane H. Hsiao Vice Chairman & Chief Technical Officer
John A. Paganelli Independent Director
Steven D. Rubin Director & Executive Vice President-Administration
Richard C. Pfenniger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
OPKO HEALTH, INC.-51.50%985
JOHNSON & JOHNSON3.06%344 670
ROCHE HOLDING AG22.19%254 722
MERCK AND COMPANY8.99%211 953
PFIZER-15.40%208 023
NOVARTIS17.78%198 320